A Study of CST-2032 and CST-107 in Subjects With Mild Cognitive Impairment or Mild Dementia Due to Parkinson's or Alzheimer's Disease
Public ClinicalTrials.gov record NCT05104463. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2a, Randomized, Placebo-Controlled, Double-Blind, Crossover Study to Evaluate the Safety, Tolerability and Effects of CST-2032 and CST-107 on Cognition in Subjects With Mild Cognitive Impairment or Mild Dementia Due to Parkinson's or Alzheimer's Disease
Study identification
- NCT ID
- NCT05104463
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- CuraSen Therapeutics, Inc.
- Industry
- Enrollment
- 64 participants
Conditions and interventions
Conditions
Interventions
- CST-2032, matching placebo for CST-2032, CST-107, matching placebo for CST-107 Drug
Drug
Eligibility (public fields only)
- Age range
- 50 Years to 85 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Apr 10, 2022
- Primary completion
- Dec 19, 2023
- Completion
- Jan 31, 2024
- Last update posted
- Jan 22, 2025
2022 – 2024
United States locations
- U.S. sites
- 14
- U.S. states
- 7
- U.S. cities
- 14
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| CuraSen Investigational Site | Scottsdale | Arizona | 85258 | — |
| CuraSen Investigational Site | Lafayette | California | 94549 | — |
| CuraSen Investigational Site | Boca Raton | Florida | 33486 | — |
| CuraSen Investigational Site | Bradenton | Florida | 34205 | — |
| CuraSen Investigational Site | Lady Lake | Florida | 32159 | — |
| CuraSen Investigational Site | Miami | Florida | 33176 | — |
| CuraSen Investigational Site | New Port Richey | Florida | 34652 | — |
| CuraSen Investigational Site | Winter Park | Florida | 32792 | — |
| CuraSen Investigational Site | New York | New York | 10003 | — |
| CuraSen Investigational Site | Cincinnati | Ohio | 45242 | — |
| CuraSen Investigational Site | Houston | Texas | 77074 | — |
| CuraSen Investigational Site | Round Rock | Texas | 78681 | — |
| CuraSen Investigational Site | Stafford | Texas | 77477 | — |
| CuraSen Investigational Site | Salt Lake City | Utah | 84102 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 1 non-U.S. site.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05104463, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jan 22, 2025 · Synced Jul 24, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT05104463 live on ClinicalTrials.gov.